Moderna reports Q4 EPS ($2.11), consensus ($2.60)

Reports Q4 revenue $678M, consensus $623.93M. “In 2025, we sharpened our commercial execution, launched our third product and brought online three international manufacturing sites, while advancing our mRNA pipeline. At the same time, we lowered our annual operating expenses by approximately $2.2B, significantly surpassing our cost-reduction targets,” said Stephane Bancel, CEO. “We entered the new year with strong momentum despite the continued challenging environment in the U.S., poised to deliver up to 10 percent revenue growth through mNEXSPIKE expansion and our international strategic partnerships. We look forward to delivering multiple potential product approvals and late-stage clinical readouts, while driving continued innovation across our mRNA platform.”